The Generic Pharmaceutical Association is on track to launch its drug shortage monitoring program after getting a green light from the Federal Trade Commission.
The association requested an advisory opinion from FTC as to whether its proposed Accelerated Recovery Initiative (ARI) would harm competition....
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?